In a collagen-based contractility assay, primary human AAA patient-derived VSMCs treated with lenvatinib displayed enhanced contractility in comparison with vehicle-treated cells (Figure 4A and Supplemental Figure 9C) and significant upregulation of contractile cell markers (i.e., MYOCD and ACTA2) 24 hours after treatment initiation (Figure 4B and Supplemental Figure 9D). This evidence concerns the gene ACTA2 and triple-A syndrome.